Company Overview and News

to your dashboard

Headline News

ClearSign Combustion's Duplex Technology Is A Commercial Failure; The Stock's Downtrend Will Continue

2018-01-05 seekingalpha
ClearSign’s green energy Duplex technology has been tested by refineries for many years but has resulted in very few adoptions. (86-1)

Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals

2017-12-24 seekingalpha
Nanjing Legend Biotech received a $350 million upfront payment from Janssen Biotech, which will form a global partnership with Legend for its highly effective CAR-T candidate. In June, Legend, which was not previously well known, surprised the annual ASCO meeting with stunningly positive results from an early trial of the CAR-T molecule in patients with multiple myeloma. In addition to the $350 million initial payment, Janssen will make unspecified development and regulatory milestone payments to Legend. (455-3)

TransEnterix & GBIL Ink Deal to Commercialize SurgiBot System

2017-12-19 zacks
TransEnterix, Inc. (TRXC - Free Report) recently signed an agreement with Great Belief International Limited (“GBIL”) to commercialize the SurgiBot System globally. Notably, TransEnterix’s SurgiBot System is a single-port, robotically enhanced laparoscopic surgical platform. (105-3)

7 'Strong Buy' Disruptive Stocks You Should Track Now | InvestorPlace

2017-12-08 investorplace
Today, I am going to focus in on seven particularly compelling stocks to share with you. These are stocks that have the power to disrupt — and have significant backing from the Street. All these stocks have a ‘Strong Buy’ rating from the best-performing analysts on TipRanks and big upside potential from the current share price. (204-4)

Transenterix Undisclosed Related Party Transactions

2017-11-27 seekingalpha
Florida Hospital Executive Medical Director Dr. Steve Eubanks has had connections with Transenterix and its Board Members. (62-7)

TRXC / TransEnterix, Inc. - Stock Institutional Ownership and Shareholders -

TransEnterix, Inc. (AMEX:TRXC) has 65 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 50,391,171 shares. Largest shareholders include Aisling Capital Iii Lp, Aisling Capital LLC, SV Life Sciences Advisers, LLC, Jp Morgan Chase & Co, and Masters Capital Management Llc. (62-10)

TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y

2017-11-10 zacks
TransEnterix Inc. (TRXC - Free Report) posted a loss of 9 cents per share in third-quarter 2017, in line with the Zacks Consensus Estimate. The company incurred a loss of 11 cents in the year-ago quarter. (70-4)

TransEnterix's (TRXC) CEO Todd Pope on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good morning ladies and gentlemen, and welcome to the TransEnterix Third Quarter 2017 Financial and Operating Results Conference Call. As a reminder, this conference call is webcast live and recorded. (77-1)

Are Options Traders Betting on a Big Move in TransEnterix (TRXC) Stock?

2017-11-06 zacks
Investors in TransEnterix, Inc. (TRXC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17, 2017 $8 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (62-6)

Study Finds Laparoscopic Surgical Robots Offer No Clinical Benefit. Will It Hurt TransEnterix Sales?

2017-11-01 seekingalpha
A study was published in reputable medical journal JAMA stating that laparoscopic surgical bots offer no clinical benefit. (62-6)

TransEnterix (TRXC) Soars: Stock Adds 12.7% in Session

2017-10-23 zacks
TransEnterix, Inc. (TRXC - Free Report) was a big mover last session, as the company saw its shares nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.26–$4.00 in the past one-month time frame, witnessed a sharp increase on Friday. (117-2)

TransEnterix Senhance Surgical Robotic System Wins FDA Nod

2017-10-16 zacks
TransEnterix, Inc. (TRXC - Free Report) announced the receipt of FDA 510(k) clearance for the Senhance Surgical Robotic System. Senhance is a multiport surgical robotic system which helps perform minimally invasive surgery.It is the first FDA-approved entrant in the field of abdominal surgical robotics since 2000. This development is going to fortify TransEnterix’s medical device robotics segment’s business. (70-6)

Technical Insights on Medical Supplies Stocks -- TransEnterix, Dextera Surgical, Mazor Robotics, and DENTSPLY SIRONA

2017-09-29 prnewswire
If you want a Stock Review on TRXC, DXTR, MZOR, or XRAY then come over to and sign up for your free customized report today. On Thursday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session flat; the Dow Jones Industrial Average edged 0.18% higher; and the S&P 500 was up 0.12%. US markets made broad based gains with six out of nine sectors finishing the day in green. (174-4)

TransEntrix Progresses Toward FDA Approval for Senhance

2017-09-20 zacks
TransEnterix Inc. (TRXC - Free Report) , a global medical technology company, recently announced that it has filed a response with the FDA related to its Senhance Surgical Robotic System 510(k) submission. The company expects to receive the FDA approval for the system in fiscal 2017 itself. (69-2)

Stock Research Report

TransEnterix, Inc. is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical challenges associated with current laparoscopic and robotic options. TransEnterix is focused on the commercialization and further development of its Senhance™ Surgical Robotic System (formerly known as the ALF-X ® Surgical Robotic System) (the “Senhance System”), a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology. The Senhance System has been granted a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, but is not available for sale in the U.S. TransEnterix has also developed the SurgiBot™ System (the “SurgiBot System”), a single-port, robotically enhanced laparoscopic surgical platform. The SurgiBot System is not available for sale in any market.

The Senhance...

Click for full article
CUSIP: 89366M201